

Juliet Barker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/810109/publications.pdf>

Version: 2024-02-01

83
papers

4,457
citations

172457
29
h-index

110387
64
g-index

83
all docs

83
docs citations

83
times ranked

5508
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1686-1693.	1.3	2
2	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1095-1100.	2.4	4
3	Racial disparities in access to alternative donor allografts persist in the era of "donors for all". <i>Blood Advances</i> , 2022, 6, 5625-5629.	5.2	12
4	Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. <i>Blood Advances</i> , 2022, 6, 6291-6300.	5.2	11
5	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. <i>Leukemia</i> , 2021, 35, 850-862.	7.2	8
6	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 289-292.	2.4	4
7	Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 286-291.	1.2	10
8	Analysis of the CD34+ cell to total nucleated cell content ratio of 619 transplanted and back-up cord blood units. <i>Bone Marrow Transplantation</i> , 2021, 56, 701-704.	2.4	2
9	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	1.3	2
10	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	1.2	11
11	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 540-544.	1.2	11
12	Human cytomegalovirus expands a CD8 ⁺ T cell population with loss of BCL11B expression and gain of NK cell identity. <i>Science Immunology</i> , 2021, 6, eabe6968.	11.9	25
13	Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature. <i>Journal of Immunology</i> , 2021, 207, 2534-2544.	0.8	4
14	Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All". <i>Blood</i> , 2021, 138, 423-423.	1.4	1
15	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 1632-1634.	2.4	0
16	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 323-332.	2.0	19
17	Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 758-763.	2.0	14
18	Evaluation of Cord Blood Total Nucleated and CD34+ Cell Content, Cell Dose, and 8-Allele HLA Match by Patient Ancestry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 734-744.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Guidelines for Cord Blood Unit Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2190-2196.	2.0	44
20	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.	5.2	29
21	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	27.0	435
22	A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1195-1202.	2.0	40
23	Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1687-1689.	2.4	9
24	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Palliative Medicine</i> , 2020, 23, 1653-1657.	1.1	1
25	Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. <i>Blood Advances</i> , 2020, 4, 191-202.	5.2	36
26	Guidelines for Cord Blood Unit Thaw and Infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1780-1783.	2.0	5
27	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	8.2	161
28	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 6656-6667.	8.2	101
29	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
30	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , 2019, 134, 924-934.	1.4	199
31	Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. <i>Transplant Infectious Disease</i> , 2019, 21, e13187.	1.7	62
32	Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2501-2506.	2.0	10
33	Regarding "Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study" <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e268-e269.	2.0	7
34	Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. <i>Blood Advances</i> , 2019, 3, 939-944.	5.2	56
35	CD34+ cell content of 126%341 cord blood units in the US inventory: implications for transplantation and banking. <i>Blood Advances</i> , 2019, 3, 1267-1271.	5.2	27
36	Paradoxical immune reconstitution inflammatory syndrome associated with disseminated tuberculosis infection in an unrelated donor cord blood transplant recipient. <i>Transplant Infectious Disease</i> , 2018, 20, e12889.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1057-1062.	2.0	15
38	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	258
39	A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2176-2176.	1.4	1
40	Burden and Impact of Geriatric Syndromes Associated with Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Blood</i> , 2018, 132, 3370-3370.	1.4	0
41	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. <i>Haematologica</i> , 2017, 102, 941-947.	3.5	15
42	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
43	Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 965-970.	2.0	31
44	Protective Factors in the Intestinal Microbiome Against <i>Clostridium difficile</i> Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017, 215, 1117-1123.	4.0	81
45	Ex Vivo CD34+Selected T CellDepleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 452-458.	2.0	35
46	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2088-2095.	2.0	9
47	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 67-74.	2.0	24
48	Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2017, 130, 747-747.	1.4	6
49	Analysis of Cyclosporine A Levels Supports New Dosing Guidelines in Adult Double-Unit Cord Blood Transplant Recipients to Optimize Immunosuppression Early Post-Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1533-1534.	2.0	9
50	Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 450-463.	5.6	95
51	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 3188-3188.	1.4	0
52	InVivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2173-2179.	2.0	21
53	Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. <i>Clinical Infectious Diseases</i> , 2015, 61, S652-S661.	5.8	32
54	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , 2015, 125, 199-205.	1.4	109

#	ARTICLE	IF	CITATIONS
55	Evaluation of Initial Telomere Length and Changes after Transplantation in Adult Double-Unit Cord Blood Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1334-1336.	2.0	5
56	Intestinal <i>Blautia</i> Is Associated with Reduced Death from Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1373-1383.	2.0	619
57	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 920-925.	2.0	33
58	Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1981-1984.	2.0	9
59	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015, 50, 1293-1298.	2.4	15
60	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2160-2166.	2.0	31
61	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1985-1993.	2.0	40
62	Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. <i>British Journal of Haematology</i> , 2015, 168, 405-412.	2.5	39
63	Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience. <i>Blood</i> , 2015, 126, 4392-4392.	1.4	4
64	Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines. <i>Blood</i> , 2015, 126, 3157-3157.	1.4	0
65	A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B-Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 354-360.	2.0	35
66	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 787-793.	2.0	43
67	Sustained Donor Engraftment in Recipients of Double-Unit Cord Blood Transplantation Is Possible Despite Donor-Specific Human Leukoctye Antigen Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 735-739.	2.0	21
68	Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution study. <i>Journal of Infection</i> , 2014, 69, 341-351.	3.3	31
69	No Wash-Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation is Safe with High Rates of Sustained Donor Engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 490-494.	2.0	18
70	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 124, 1174-1182.	1.4	711
71	Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. <i>Blood</i> , 2014, 124, 2905-2912.	1.4	74
72	Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect. <i>Blood</i> , 2014, 124, 2459-2459.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Quantitative Assessment of T Cell Repertoire Recovery after Double Unit Cord Blood Transplantation Demonstrates Early T Cell Diversity and Correlation Between CMV Reactivation and CD8 Clonal Dominance. <i>Blood</i> , 2014, 124, 1158-1158.	1.4	0
74	Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients. <i>Blood</i> , 2013, 122, 3297-3297.	1.4	1
75	Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1124-1129.	1.3	41
76	Telomere Length Plays No Role in Clinical Unit Dominance After Double-Unit Cord Blood Transplantation. <i>Blood</i> , 2012, 120, 4661-4661.	1.4	0
77	Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience. <i>Blood</i> , 2012, 120, 1996-1996.	1.4	0
78	Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. <i>Blood</i> , 2010, 116, 5045-5049.	1.4	212
79	Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1541-1548.	2.0	145
80	A "No-wash" Albumin-Dextran Dilution Strategy for Cord Blood Unit Thaw: High Rate of Engraftment and a Low Incidence of Serious Infusion Reactions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1596-1602.	2.0	69
81	Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.. <i>Blood</i> , 2009, 114, 2296-2296.	1.4	6
82	Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.. <i>Blood</i> , 2007, 110, 1658-1658.	1.4	0
83	Analysis of 608 Umbilical Cord Blood (UCB) Transplants: HLA-Match Is a Critical Determinant of Transplant-Related Mortality (TRM) in the Post-Engraftment Period Even in the Absence of Acute Graft-vs-Host Disease (aGVHD).. <i>Blood</i> , 2005, 106, 303-303.	1.4	14